Ogata M, Ogata Y, Imamura T, Ohtsuka E, Kikuchi H, Utsunomiya A, Yashiki S, Sonoda S, Nasu M
Second Department of Internal Medicine, Oita Medical University, Oita, Japan.
Bone Marrow Transplant. 2002 Nov;30(10):699-701. doi: 10.1038/sj.bmt.1703702.
We report a 51-year-old male with adult T cell leukemia (ATL) who received a BMT from an HLA-identical unrelated donor. The ATL proved refractory to chemotherapy, and he underwent BMT conditioned with CY/TBI. Complications of encephalitis of unknown origin were successfully treated with steroid therapy and the patient has been in CR for 16 months after BMT. Human T cell leukemia virus type 1 proviral DNA loads were reduced to undetectable levels in PBMC sampled 12 months after BMT. This encouraging result suggests that BMT from an unrelated donor should be considered for ATL even if the disease is refractory to chemotherapy.
我们报告了一名51岁患有成人T细胞白血病（ATL）的男性，他接受了来自一名HLA匹配的无关供者的骨髓移植（BMT）。该ATL对化疗耐药，他接受了环磷酰胺/全身照射（CY/TBI）预处理的BMT。不明原因的脑炎并发症通过类固醇治疗成功治愈，患者在BMT后已持续完全缓解（CR）16个月。在BMT后12个月采集的外周血单个核细胞（PBMC）中，1型人类T细胞白血病病毒前病毒DNA载量降至检测不到的水平。这一令人鼓舞的结果表明，即使疾病对化疗耐药，对于ATL患者也应考虑进行无关供者的BMT。
